CSIMarket
 

Supernus Pharmaceuticals inc   (SUPN)
Other Ticker:  
 

Supernus Pharmaceuticals Inc 's Working Capital Per Sales

SUPN's Working Capital and Revenue growth



SUPN Working Capital Per Revenue (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Working Capital Change 236.52 % 804.72 % -64.21 % -52.77 % -82.97 %
Y / Y Revenue Change -13.24 % -20.28 % 0.82 % 5.2 % 19.46 %
Working Capital Per Revenue 0.41 0.3 0.18 0.28 0.37
Total Ranking # 924 # 1274 # 1274 # 1 # 688
Seq. Working Capital Change 1.42 % 110.66 % -23.28 % 105.31 % 172.65 %
Seq. Revenue Change 13.51 % -11.84 % -8.11 % -5.65 % 4.29 %





Comment on SUPN's Working Capital Per Revenue in the third quarter 2023
Supernus Pharmaceuticals Inc 's Working Capital Per Revenue sequentially grew to 0.41 during the Q3 2023, below the Supernus Pharmaceuticals Inc average. Due to increase of revenue in the Q3 2023 year on year by -13.24%.

Within Healthcare sector 6 other companies have achieved lower Working Capital Per Revenue during the Q3 2023. While Supernus Pharmaceuticals Inc Working Capital Per Revenue overall ranking has impoved so far in the Q3 2023 to 924, from total ranking in the second quarter 2023 at 1274.
Working Capital Per Revenue Ranking
Within: No.
Industry # 1
Sector # 7
S&P 500 # 924


Working Capital Per Revenue Statistics
High Average Low
6.08
0.71
0.01
(Dec. 30, 2013)   (Mar 31 2023)



Financial Statements
Supernus Pharmaceuticals Inc 's Working Capital $ 324 Millions Visit SUPN's Balance sheet
Supernus Pharmaceuticals Inc 's Revenues $ 154 Millions Visit SUPN's Income Statement
Where are SUPN's Sales coming from? Visit SUPN's Sales by Geography




Companies with similar Average Working Capital Per Revenue for 12 months ending Sep 30 2023, within Healthcare Sector Working Capital Per Revenue
Nanostring Technologies Inc   1.10 
Alnylam Pharmaceuticals Inc   1.10 
Nevro Corp   1.09 
Vertex Pharmaceuticals Inc  1.09 
Fonar Corporation  1.09 
Regeneron Pharmaceuticals Inc   1.06 
Omniab Inc   1.05 
Alpha Teknova Inc   1.04 
Y mabs Therapeutics inc   1.04 
Innoviva Inc   1.03 
Spero Therapeutics Inc   1.02 
Arcturus Therapeutics Holdings Inc   1.02 
Treace Medical Concepts Inc   1.02 
Cue Health Inc   1.02 
Intercept Pharmaceuticals inc   1.01 
Coherus Biosciences inc   1.01 
Ispecimen inc   1.00 
Icad Inc  1.00 
Caredx Inc   0.98 
Venus Concept Inc   0.98 
Sunshine Biopharma Inc   0.98 
Adma Biologics Inc   0.98 
Ardelyx Inc   0.98 
Iradimed Corporation  0.98 
Exagen Inc   0.97 
Bio rad Laboratories Inc   0.96 
23andme Holding Co  0.95 
Biomarin Pharmaceutical Inc  0.93 
Seres Therapeutics Inc   0.92 
Amgen Inc   0.92 
Date modified: 2023-11-09T22:44:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com